Dr. Ronald C. Hendrickson, is the director of Proteomics in the department of Molecular Profiling at Merck Research Laboratories in Rahway, New Jersey, USA.
is applying state-of-the-art mass spectrometry techniques to rapidly identify and quantify changes in proteins related to disease or therapeutic agents.
Prior to joining Merck, Dr. Hendrickson served as a Vice President for MDS Proteomics (Protana), a leading proteomics company founded on emerging informatics tools and nano-electrospray technology developed the EMBL.
He also served as Chairman of the MDS Proteomics-Harvard Partners Joint Steering Committee.
This strategic alliance was established to combine the collective expertise of clinical investigators and state of the art proteomics to speed the discovery, development and commercialization of innovative healthcare products.
Dr. Hendrickson joined Protana in Odense Denmark to work with Matthias Mann and Ole Vorm At Protana, his research efforts expanded into large-scale protein-protein interaction studies using yeast as a model organism.
Prior to joining Protana, Dr. Hendrickson was employed by Corixa Corporation in Seattle, Washington, USA.
His research at Corixa involved identifying tumor antigens and serological markers for Breast cancer and Tuberculosis.
Dr. Hendrickson received his B.S. in Chemistry from the University of Washington and his Ph.D. in Chemistry from the University of Virginia.
Under the guidance of Professor Donald F. Hunt, Dr. Hendrickson
developed and applied high-sensitivity mass spectrometry to biological research.